Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
tPA tissue plasminogen activator is produced by using recombinant technology techniques known as recombinant tissue plasminogen activator (rtPA). Specific rtPAs are tenecteplase, alteplase, and reteplase. These enzymes are used in clinical treatment of thrombotic stroke or embolic stroke. tPA is a drug that dissolves blood clots. It is a thrombolytic agent which can be administrated into the veins.
Rising burden of pulmonary embolism in individuals globally, is expected to propel the growth of the market over the forecast period.
For instance, according to Centers for Disease Control and Prevention report published in 2019, approximately 900,000 Americans were affected due to pulmonary embolism and about 10-20 % individuals die after 1 month of diagnosis.
The global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2022 and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).
Figure 1. Global Tissue Plasminogen Activator Market Share (%) in Terms of Value, By Region, 2020
Increasing Incidence of Stroke is expected to drive the market growth over the forecast period
Tissue plasminogen activator (tPA) is an enzyme associated with the disintegration of blood clots. It is a serine protease present in endothelial cells. With the help of serine protease, the conversion of plasminogen to plasmin is catalyzed. Serine protease is a major enzyme for clot disintegration.
Tissue plasminogen activator is the first and only drug approved by the U.S. FDA in 1996 for the treatment of acute ischemic stroke. The increasing incidence of stroke is expected to drive the market growth during the forecast period.
For instance, according to the World Health Organization (WHO), in 2015, stroke is the second leading global cause of death after heart disease and it accounted for 11.8% of total deaths worldwide.
Furthermore, according to the Centers for Disease Control and Prevention, in 2018, 1 in every 6 deaths from cardiovascular disease was due to stroke in the U.S.
Figure 2. Global Tissue Plasminogen Activator Market Share (%), by Drug Type, 20220
The increasing prevalence of stroke in growing geriatric population is another major factor driving the market size. As per the Public Health England (PHE), around 38% of people suffering from strokes were aged between 40 to 69 years in 2018.
Moreover, tissue plasminogen activator market revenue is witnessing further increase due to awareness about stroke and its symptoms. In 2015, the Centers for Disease Control and Prevention (CDC) stated that around 38% of people were able to recognize the major symptoms of stroke and were treated at the right time.
Tissue Plasminogen Activator Market Report Coverage
||Market Size in 2022:
||US$ 2,455.4 Mn
|Historical Data for:
||2017 to 2020
||2020 to 2027
|Forecast Period 2021 to 2028 CAGR:
||2027 Value Projection:
||US$ 3,491.5 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Alteplase, Reteplase, Tenecteplase
- By Application: Ischemic Stroke, Myocardial Infarction, Pulmonary Embolism, Thrombolysis, Others
F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences
- Increasing number of pipeline product
- Increasing prevalence of stroke
|Restraints & Challenges:
- Side effect of tissue plasminogen activator drugs
Global Tissue Plasminogen Activator Market– Impact of Coronavirus (Covid-19) Pandemic
The tissue plasminogen activators such as alteplase, reteplase, and tenecteplase have wide application for treatment of disease conditions such as ischemic stroke, myocardial Infarction, pulmonary embolism, and deep vein thrombosis. Moreover, many patients suffering from cardiovascular diseases such as ischemia heart diseases, hypertension, and others are at a higher risk of contracting COVID-19. Thus, for the treatment of these symptoms along with COVID-19, doctors prescribe drugs such as hydroxychloroquine, azithromycin, and altepase, and this has had a positive impact on the global tissue plasminogen activator market during COVID-19.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 136 million infected individuals worldwide as of April 12, 2021.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to the transportation of drugs and devices from one place to another.
Global Tissue Plasminogen Activator Market Restraint
The side effects such as nausea, vomiting, dizziness, and fever, of the tissue plasminogen activator drugs is one of the factors hindering tissue plasminogen activator market growth. Major side effects include hypertension, intracranial hemorrhage, systemic hemorrhage, angioedema, and others. tPA causes complications of left ventricle as well.
According to the National Center for Biotechnology Information, around 2% to 5% of patients with acute ischemic stroke received rtPA in the U.S. In 2015, Centers for Disease Control and Prevention (CDC) reported around 140,000 deaths due to unavailability and adverse effects of tPA in the U.S.
Moreover, tissue plasminogen activator market growth can be hampered by substitute product approvals by the U.S. Food and Drug Administration (FDA). For instance, after the approval of stent retriever by the U.S. FDA in 2012, the global tissue plasminogen activator market growth was affected, since tPA is not effective for major blood clots in comparison to the stent retriever thrombectomy.
Major players operating in the global tissue plasminogen activator market include include F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences